| Gonzalez, Humberto C |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
| Alkhouri, Naim |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc., Galectin Therapeutics Inc | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
| Active, not recruiting | 2a | 89 | US | HPG1860, Placebo | Hepagene (Shanghai) Co., Ltd. | NASH - Nonalcoholic Steatohepatitis | 02/23 | 03/23 | | |
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 42 | Europe, US | IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | 03/24 | 06/24 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
NCT05490888: Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics |
|
|
| Recruiting | 1 | 62 | US | PHIN-214 Subcutaneous injection, Terlipressin derivative | PharmaIN | Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic | 10/25 | 12/25 | | |
NCT05916560: A Study of LY3437943 in Participants With Impaired and Normal Liver Function |
|
|
| Recruiting | 1 | 37 | US | LY3437943 | Eli Lilly and Company | Healthy, Hepatic Insufficiency | 03/25 | 03/25 | | |
NCT04054310: Non-Invasive Quantification of Liver Health in NASH (N-QUAN) |
|
|
| Recruiting | N/A | 225 | US | Liver Multi Scan, Biopsy | Perspectum | NASH - Nonalcoholic Steatohepatitis | 05/24 | 05/24 | | |
| Davis, Steven A |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriasis, Obesity | 12/25 | 05/26 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Active, not recruiting | 3 | 1108 | Europe, Canada, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 12/24 | 11/25 | | |
NCT06163404: Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant |
|
|
| Recruiting | N/A | 50 | US | Implantation of Spirair Nasal Device using the Spirair delivery system., SeptAlign | Spirair, Inc | Nasal Septal Deviation, Nasal Airway Obstruction | 12/24 | 07/25 | | |
NCT06477172: Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures |
|
|
| Recruiting | N/A | 500 | Canada, US | | Acorn Biolabs Inc. | Post Procedural Erythema | 02/25 | 02/25 | | |
| Phillips, Raymond W |
| Completed | 3 | 200 | US | Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo | Cristcot LLC, Cristcot HCA LLC | Ulcerative Proctitis | 07/24 | 09/24 | | |
| Recruiting | 3 | 396 | Canada, US | Vedolizumab, Entyvio, MLN0002, KYNTELES, Upadacitinib, Rinvoq, Placebo | Takeda | Crohn's Disease | 06/27 | 08/28 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
| Active, not recruiting | 2 | 60 | US | Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo | Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc. | Primary Biliary Cholangitis | 11/24 | 02/25 | | |
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis |
|
|
| Active, not recruiting | 1/2 | 42 | US | CNP-104, Placebo | COUR Pharmaceutical Development Company, Inc. | Primary Biliary Cholangitis | 01/26 | 01/26 | | |
| Recruiting | 1/2 | 73 | US | REC-4881, Placebo | Recursion Pharmaceuticals Inc. | Familial Adenomatous Polyposis | 07/26 | 07/26 | | |
| Active, not recruiting | N/A | 1900 | US | Multi-analyte blood Test | Helio Genomics | Liver Cirrhosis | 02/23 | 06/24 | | |
| Recruiting | N/A | 4000 | Canada, US | None - Observational, Observational | American Gastroenterological Association, OpenBiome, University of California, San Diego, Commure, University of Pennsylvania, University of Minnesota, Loyola University Chicago | Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome | 08/27 | 08/27 | | |
| Carpio, Jose M |
NCT05264506: Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive |
|
|
| Terminated | 3 | 2007 | US | NOMAC-E2 COC, Nomegestrol acetate / estradiol | Organon and Co, IQVIA Inc., OSTAtistics | Contraception | 01/24 | 01/24 | | |
| Completed | 3 | 397 | Europe, Canada, Japan, US, RoW | GSK3511294, Depemokimab, Placebo | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 04/24 | 04/24 | | |
|
SIS, NCT06597344: A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis) |
|
|
| Recruiting | 3 | 90 | US | Gepotidacin | GlaxoSmithKline | Urinary Tract Infections | 03/25 | 03/25 | | |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults |
|
|
| Completed | 2 | 797 | NA | ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline | AEON Biopharma, Inc., PPD | Migraine | 06/24 | 08/24 | | |
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy |
|
|
| Recruiting | 1/2 | 192 | Canada, US | Peanut SLIT-tablet, Placebo | ALK-Abelló A/S, Parexel | Peanut Allergy | 01/26 | 02/26 | | |
NCT05138822: Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections |
|
|
| Completed | 1 | 140 | US | GSK3882347, Nitrofurantoin, Placebo | GlaxoSmithKline | Uncomplicated Urinary Tract Infections, Urinary Tract Infections | 12/24 | 12/24 | | |
| Soufer, Joseph |
| Completed | 4 | 580 | US | Galcanezumab, LY2951742, Rimegepant, Placebo | Eli Lilly and Company | Migraine, Episodic Migraine | 05/23 | 05/23 | | |
|
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) |
|
|
| Completed | 4 | 152 | US | Tirzepatide, LY3298176 | Eli Lilly and Company | Type 2 Diabetes, Diabetes Mellitus, Type 2 | 10/23 | 10/23 | | |
NCT05590403 / 2022-001981-36: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above |
|
|
| Completed | 3 | 1544 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA investigational vaccine, Placebo | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 03/23 | 04/24 | | |
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
|
|
| Active, not recruiting | 3 | 1083 | Europe, Canada, US, RoW | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 12/24 | 02/25 | | |
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin |
|
|
| Recruiting | 3 | 888 | Europe, US, RoW | Orforglipron, LY3502970, Dapagliflozin | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 10/25 | | |
NCT06015282: The Celljuvant Study: a Phase 3 Immunogenicity and Safety Study of AQIVc Vaccine in Adults Aged 50 Years and Older |
|
|
| Active, not recruiting | 3 | 7741 | Europe, Canada, US, RoW | Investigational aQIVc, licensed QIV1, licensed QIV2 | Seqirus | Influenza, Human | 03/24 | 01/25 | | |
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections |
|
|
| Completed | 3 | 730 | Europe, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar | Eli Lilly and Company, Eli Lilly and Company | Type 2 Diabetes, Type 2 Diabetes Treated With Insulin | 02/24 | 02/24 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 795 | US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, T2D | 07/24 | 07/24 | | |
ACHIEVE-5, NCT06109311: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor |
|
|
| Recruiting | 3 | 520 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Type 2 Diabetes | 06/25 | 06/25 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hypertension |
|
|
| Enrolling by invitation | 3 | 1400 | Europe, Canada, US, RoW | lorundrostat, Placebo | Mineralys Therapeutics Inc. | Hypertension | 12/25 | 12/26 | | |
| Active, not recruiting | 3 | 1800 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Cardiovascular Diseases | 01/26 | 02/26 | | |
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee |
|
|
| Active, not recruiting | 3 | 405 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteo Arthritis Knee | 02/26 | 03/26 | | |
| Active, not recruiting | 3 | 2300 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | 04/26 | 05/26 | | |
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight |
|
|
| Active, not recruiting | 3 | 1000 | Europe, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | 05/26 | 05/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease |
|
|
| Active, not recruiting | 3 | 17004 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 10/27 | 10/27 | | |
| Active, not recruiting | 3 | 14013 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 04/29 | 04/29 | | |
OA05, NCT05620563: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain |
|
|
| Completed | 2 | 147 | US | LY3857210, Placebo | Eli Lilly and Company | Osteoarthritis | 06/23 | 06/23 | | |
NCT05630196: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain |
|
|
| Completed | 2 | 138 | US | LY3857210, Placebo | Eli Lilly and Company | Chronic Low-back Pain | 06/23 | 06/23 | | |
NCT05620576: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05). |
|
|
| Completed | 2 | 131 | US | LY3857210, Placebo | Eli Lilly and Company | Diabetic Peripheral Neuropathic Pain | 07/23 | 08/23 | | |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Active, not recruiting | 2 | 285 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 01/25 | 02/25 | | |
| Completed | 2 | 204 | Europe, Canada, Japan, US, RoW | LY3561774, Placebo | Eli Lilly and Company | Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia | 03/24 | 05/24 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
NCT06037252: A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity |
|
|
| Recruiting | 2 | 350 | US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity | 01/26 | 10/26 | | |
NCT06074562: A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain |
|
|
| Recruiting | 2 | 410 | Europe, Japan, US, RoW | LY3556050, Placebo | Eli Lilly and Company | Diabetic Peripheral Neuropathy | 07/25 | 07/25 | | |
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain |
|
|
| Recruiting | 2 | 10000 | US | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo | Eli Lilly and Company | Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain | 04/27 | 04/27 | | |
| Active, not recruiting | N/A | 44467 | US | | Guardant Health, Inc., Premier Research Group plc | Colorectal Cancer | 03/24 | 12/25 | | |
| Recruiting | N/A | 925 | US | Blood glucose meter, Eversense CGM System | Senseonics, Inc. | Diabetes | 03/26 | 03/26 | | |
| Davis, Stacey |
| Recruiting | 2 | 850 | Europe, US, RoW | CVL-231 30 mg, Emraclidine | Cerevel Therapeutics, LLC | Schizophrenia | 02/26 | 02/26 | | |
| Fatakia, Adil |
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin |
|
|
| Recruiting | 3 | 888 | Europe, US, RoW | Orforglipron, LY3502970, Dapagliflozin | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 10/25 | | |
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy |
|
|
| Active, not recruiting | 3 | 61 | Europe, US, RoW | Secukinumab, AIN457, Placebo | Novartis Pharmaceuticals | Rotator Cuff Tendinopathy | 10/24 | 12/24 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Recruiting | 2/3 | 560 | US | IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo | Incannex Healthcare Ltd | Obstructive Sleep Apnea | 12/26 | 12/26 | | |
NCT04809376: Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain |
|
|
| Active, not recruiting | 2/3 | 602 | US, RoW | Pentosan Polysulfate Sodium twice weekly, PPS twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Placebo, Pentosan Polysulfate Sodium Fixed Dose, Fixed Dose, Pentosan Polysulfate Sodium once weekly, PPS once weekly | Paradigm Biopharmaceuticals USA (INC) | Osteoarthritis, Knee | 10/24 | 01/25 | | |
NCT06373146: A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity |
|
|
| Recruiting | 2 | 360 | US, RoW | Tirzepatide, LY3298176, Mibavademab, REGN4461, Tirzepatide-Placebo, Mibavademab-Placebo | Eli Lilly and Company, Regeneron Pharmaceuticals | Obesity | 12/25 | 04/26 | | |
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults |
|
|
| Completed | 2 | 797 | NA | ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline | AEON Biopharma, Inc., PPD | Migraine | 06/24 | 08/24 | | |
| Recruiting | 2 | 150 | US | CYR-064 | Cyrano Therapeutics, Inc. | Hyposmia | 06/25 | 06/25 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain |
|
|
| Recruiting | 2 | 384 | US | RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo | Reata, a wholly owned subsidiary of Biogen | Diabetic Peripheral Neuropathic Pain | 08/26 | 08/26 | | |
| Terminated | N/A | 800 | US | rapid in vitro diagnostic test, Sinu-Test®, bacterial culture, PCR assay | ENTvantage Dx, Beaufort | Sinusitis Bacterial | 04/23 | 04/23 | | |
NCT06163404: Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant |
|
|
| Recruiting | N/A | 50 | US | Implantation of Spirair Nasal Device using the Spirair delivery system., SeptAlign | Spirair, Inc | Nasal Septal Deviation, Nasal Airway Obstruction | 12/24 | 07/25 | | |
NCT05591989: Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects with Chronic Rhinitis (PARAGON) |
|
|
| Active, not recruiting | N/A | 80 | US | NEUROMARK System | Neurent Medical | Chronic Rhinitis | 06/25 | 06/25 | | |
| Reiss, Gary |
NCT06379893: A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain |
|
|
| Active, not recruiting | 4 | 195 | Europe, US | Voltaren Gel 1% (diclofenac sodium) (US only), Voltaren Gel 1.16% (diclofenac diethylammonium) (EU only), Voltaren Gel 2.32% (diclofenac diethylammonium) (EU only) | HALEON | Pain | 10/24 | 10/24 | | |
NCT05303636: LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women |
|
|
| Recruiting | 4 | 1710 | US | LF111 (drospirenone 4 mg oral tablet) or drospirenone (DRSP) 3.5 mg chewable tablet | Insud Pharma, Chemo Research | Change in Bone Mineral Density, Bone Loss | 07/26 | 03/27 | | |
| Recruiting | 3 | 612 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 2b | 357 | Europe, Canada, US, RoW | belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo | Galectin Therapeutics Inc., Galectin Therapeutics Inc | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 12/24 | 12/24 | | |
NCT05591079: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH |
|
|
| Completed | 2 | 99 | US | CS0159 (Linafexor), placebo | Cascade Pharmaceuticals, Inc, Laboratory Corporation of America | Nonalcoholic Steatohepatitis (NASH) | 11/23 | 11/23 | | |
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
|
|
| Completed | 2 | 42 | Europe, US | IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | 03/24 | 06/24 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 207 | Europe, Canada, Japan, US, RoW | TAK-279, Zasocitinib, Placebo | Takeda | Ulcerative Colitis | 09/26 | 08/27 | | |
GLY-200-03, NCT06259981: A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity |
|
|
| Active, not recruiting | 2 | 75 | US | GLY-200, Placebo | Glyscend, Inc. | Obesity | 12/24 | 12/24 | | |
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis |
|
|
| Active, not recruiting | 2 | 219 | US | HU6, Placebo | Rivus Pharmaceuticals, Inc. | Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver | 02/25 | 04/25 | | |
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease |
|
|
| Not yet recruiting | 2 | 393 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline | Liver Diseases, Alcoholic | 12/26 | 03/27 | | |
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects |
|
|
| Recruiting | 2 | 240 | US, RoW | HM15211, Placebo of HM15211 | Hanmi Pharmaceutical Company Limited | NASH - Nonalcoholic Steatohepatitis | 05/26 | 11/26 | | |
| Recruiting | 2 | 48 | US | GSK4532990 | GlaxoSmithKline | Non-alcoholic Fatty Liver Disease | 06/25 | 06/25 | | |
| Active, not recruiting | 2 | 271 | Europe, Canada, Japan, US, RoW | GSK4532990, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease | 12/25 | 03/26 | | |
CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain |
|
|
| Recruiting | 2 | 384 | US | RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo | Reata, a wholly owned subsidiary of Biogen | Diabetic Peripheral Neuropathic Pain | 08/26 | 08/26 | | |
| Recruiting | 1/2 | 73 | US | REC-4881, Placebo | Recursion Pharmaceuticals Inc. | Familial Adenomatous Polyposis | 07/26 | 07/26 | | |
NCT05743010: A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 1b | 36 | US | APL-1401, Nepicastat, SYN117, Placebo | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Ulcerative Colitis | 03/25 | 04/25 | | |
NCT05490888: Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics |
|
|
| Recruiting | 1 | 62 | US | PHIN-214 Subcutaneous injection, Terlipressin derivative | PharmaIN | Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic | 10/25 | 12/25 | | |
| Recruiting | N/A | 925 | US | Blood glucose meter, Eversense CGM System | Senseonics, Inc. | Diabetes | 03/26 | 03/26 | | |
| Rosenthal, Jon |
| Recruiting | 2 | 150 | US | CYR-064 | Cyrano Therapeutics, Inc. | Hyposmia | 06/25 | 06/25 | | |
| Lovelace, Luke |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
